What you do now, matters for a lifetime

Harness the healing power of SuperSaturated Oxygen (SSO₂) Therapy to reduce the risk of heart failure

TherOx® SuperSaturated Oxygen (SSO₂) Therapy

The first FDA-approved, catheter-based therapy to safely and effectively reduce infarct size in randomized control trials.^2,3

The Next Frontier in STEMI

Delivers localized hyperoxemic levels of oxygen to treat ischemic myocardium, without impacting door-to-balloon time.

Brochure

Infarct Size Reduction

Studies show 26% relative infarct size reduction and improvement of left ventricular function in LAD STEMI.^2,3,4,5

Publication

Low Rate of Death and Heart Failure at 1 Year

Treatment with SSO₂ was associated with a lower 1-year rate of all-cause death or new-onset heart failure (HF) of hospitalization for HF (0.0% vs. 12.3%, p = .001).⁶

Publication

Reduce endothelial edema and restore microvascular flow to reduce infarct size.

SuperSaturated Oxygen (SSO₂) Therapy has been shown to reduce endothelial swelling and restore microvascular flow, leading to reductions in infarct size.^7*

90% of myocardial blood flow is supplied by the microvasculature.⁸

Microvascular obstruction is strongly associated with mortality and heart failure hospitalization within 1 year.⁹

Significant Clinical Benefit

A 26% relative reduction in infarct size has been correlated with relative reductions in both death and heart failure hospitalization of ~25% at 1 year.⁴

Infarct Size Reduction with SSO₂ vs. Standard of Care²

Infarct Size Reduction with SSO2 vs Standard of Care

A 41% relative reduction in infarct size observed for patients receiving PCI ≤ 3 hours of symptom onset¹⁰

Left Ventricular Recovery Demonstrated at 30 Days^4,5

SSO₂ Therapy demonstrates reduced LV remodeling at 30 days^4,5

SSO2 relieves microvascular obstruction to reperfuse ischemic myocardium.

How TherOx SSO₂ Therapy Works

Capillary constriction continues post-PCI

Despite successful PCI, endothelial edema occurs and restricts microvascular flow.

Highly concentrated O2 diffuses into endothelial and myocardial tissue

Highly concentrated O₂ diffuses into endothelial and myocardial tissue

SSO₂ Therapy delivers high levels of dissolved O₂ (pO2 = 760-1000mmHg), via the plasma, even before flow is restored downstream.

Microvascular flow is restored and ischemic myocardium reperfused

Endothelial edema is resolved, restoring capillary flow and reperfusing ischemic myocardium.

Publications, News & Updates

Patient treated with SSO₂ survives his "widow maker" heart attack.

Watch Video Now

Read the winning cases from our TCT Cases & Cocktails Fellows Competition, published in Cardiac Interventions Today.

Read the article

Daytime Chicago segment featuring Sandeep Nathan, MD on SSO₂ Therapy

Watch Video Now

Novel Therapeutic Strategies to Reduce Reperfusion Injury After AMI

Read the article

ZOLL Awarded Diagnostic and Interventional Cardiology Catheter Agreement with Premier, Inc. for
TherOx SuperSaturated Oxygen Therapy

Read the article

* As observed in animal studies.
1.Jenča D, et al. ESC Heart Failure. 2021;8:222-237.
2.Stone GW, et al. Circ Cardiovasc Interv; 2; 366-375. Sep 2009.
3.O’Neill WW, et al. J Am Coll Cardiol. 2007;50; No.5. 397-405.
4.Warda HM, et al. (2005). Am J Cardiol 96(1): 22-24.
5.David SW, et al. Catheter Cardiovasc Interv. 2018;1–9.
6.Chen, et al. Catheter Cardiovasc Interv. 2020;1–7.
7.Kloner, et al. J Am Coll Cardiol Basic Trans Science. 2021:1–7.
8.Trifunovic, et al. J Hypertens Res 2019;5(1):8–20.
9.de Waha S et al. Eur Heart J 2017;38:3502-10.
10.Subset data of Stone GW, et al. Circ Cardiovasc Interv; 2; 366-375. Sep 2009. Data on file at TherOx, Inc. and CRF.

Please refer to IFU for full cautions, warnings and Indications for Use.

Caution: Federal law restricts this device to sale by or on the order of a physician.

Indications For Use: The TherOx DownStream System is indicated for the preparation and delivery of SuperSaturated Oxygen Therapy (SSO₂ Therapy) to targeted ischemic regions perfused by the patient’s left anterior descending coronary artery immediately following revascularization by means of percutaneous coronary intervention (PCI) with stenting that has been completed within 6 hours after the onset of anterior acute myocardial infarction (AMI) symptoms caused by a left anterior descending artery infarct lesion.

TherOx® SuperSaturated Oxygen (SSO₂) Therapy

TherOx® SuperSaturated Oxygen (SSO₂) Therapy

1 in 5 Patients Develop Heart Failure Following an AMI¹

Introducing the Next Frontier in STEMI Care

Contact Us

What you do now, matters for a lifetime

TherOx® SuperSaturated Oxygen (SSO₂) Therapy

The Next Frontier in STEMI

Infarct Size Reduction

Low Rate of Death and Heart Failure at 1 Year

Significant Clinical Benefit

Infarct Size Reduction with SSO₂ vs. Standard of Care²

A 41% relative reduction in infarct size observed for patients receiving PCI ≤ 3 hours of symptom onset¹⁰

Left Ventricular Recovery Demonstrated at 30 Days^4,5

SSO₂ Therapy demonstrates reduced LV remodeling at 30 days^4,5

How TherOx SSO₂ Therapy Works

Capillary constriction continues post-PCI

Highly concentrated O₂ diffuses into endothelial and myocardial tissue

Microvascular flow is restored and ischemic myocardium reperfused

Publications, News & Updates

Patient treated with SSO₂ survives his "widow maker" heart attack.

Read the winning cases from our TCT Cases & Cocktails Fellows Competition, published in Cardiac Interventions Today.

Daytime Chicago segment featuring Sandeep Nathan, MD on SSO₂ Therapy

Novel Therapeutic Strategies to Reduce Reperfusion Injury After AMI

ZOLL Awarded Diagnostic and Interventional Cardiology Catheter Agreement with Premier, Inc. for
TherOx SuperSaturated Oxygen Therapy

TherOx® SuperSaturated Oxygen (SSO2) Therapy

TherOx® SuperSaturated Oxygen (SSO2) Therapy

1 in 5 Patients Develop Heart Failure Following an AMI1

Introducing the Next Frontier in STEMI Care

Contact Us

What you do now, matters for a lifetime

TherOx® SuperSaturated Oxygen (SSO2) Therapy

The Next Frontier in STEMI

Infarct Size Reduction

Low Rate of Death and Heart Failure at 1 Year

Significant Clinical Benefit

Infarct Size Reduction with SSO2 vs. Standard of Care2

A 41% relative reduction in infarct size observed for patients receiving PCI ≤ 3 hours of symptom onset10

Left Ventricular Recovery Demonstrated at 30 Days4,5

SSO2 Therapy demonstrates reduced LV remodeling at 30 days4,5

How TherOx SSO2 Therapy Works

Capillary constriction continues post-PCI

Highly concentrated O2 diffuses into endothelial and myocardial tissue

Microvascular flow is restored and ischemic myocardium reperfused

Publications, News & Updates

Patient treated with SSO2 survives his "widow maker" heart attack.

Read the winning cases from our TCT Cases & Cocktails Fellows Competition, published in Cardiac Interventions Today.

Daytime Chicago segment featuring Sandeep Nathan, MD on SSO2 Therapy

Novel Therapeutic Strategies to Reduce Reperfusion Injury After AMI

ZOLL Awarded Diagnostic and Interventional Cardiology Catheter Agreement with Premier, Inc. for TherOx SuperSaturated Oxygen Therapy

TherOx® SuperSaturated Oxygen (SSO₂) Therapy

TherOx® SuperSaturated Oxygen (SSO₂) Therapy

1 in 5 Patients Develop Heart Failure Following an AMI¹

TherOx® SuperSaturated Oxygen (SSO₂) Therapy

Infarct Size Reduction with SSO₂ vs. Standard of Care²

A 41% relative reduction in infarct size observed for patients receiving PCI ≤ 3 hours of symptom onset¹⁰

Left Ventricular Recovery Demonstrated at 30 Days^4,5

SSO₂ Therapy demonstrates reduced LV remodeling at 30 days^4,5

How TherOx SSO₂ Therapy Works

Highly concentrated O₂ diffuses into endothelial and myocardial tissue

Patient treated with SSO₂ survives his "widow maker" heart attack.

Daytime Chicago segment featuring Sandeep Nathan, MD on SSO₂ Therapy

ZOLL Awarded Diagnostic and Interventional Cardiology Catheter Agreement with Premier, Inc. for
TherOx SuperSaturated Oxygen Therapy